Share

Phase III LINC 4 Study Confirms Efficacy and Safety of Osilodrostat in Patients with Cushing’s Disease

Positive results from the Phase III LINC 4 study have confirmed the efficacy and safety of osilodrostat, an oral therapy for patients with Cushing’s disease. The results were published in The Journal of Clinical Endocrinology & Metabolism. Recordati Rare Diseases is marketing the drug as ISTURISA®. The LINC 4 study augments the efficacy and safety...
Share

Hammer Wins Inaugural Endocrine Images Art Competition

Hammer_2020 Gary Hammer, MD, PhD, Millie Schembechler professor of Adrenal Cancer at the University of Michigan in Ann Arbor, Mich., won the Endocrine Society’s Endocrine Images Art Competition, a contest celebrating the beauty of endocrine science. Entries were judged based on aesthetic value and significance to endocrine research. Hammer’s image of the adrenal gland took the top...
Share

Brainstorming: Q&A with Michael W. Schwartz, MD

Schwartz_Headshot-cropped Endocrine News talks to Michael W. Schwartz, MD, the 2022 Laureate recipient of the Roy O. Greep Award for Outstanding Research about his life and career in academic research that all started with a fascination with how the brain controls behavior. With his significant contributions in uncovering how our brain regulates energy balance and glucose...
Share

Endocrine-Disrupting Chemicals May Impair Bone Health in Teen Boys

Per- and polyfluoroalkyl substances (PFAS) and phthalates (two types of endocrine-disrupting chemicals) may be associated with lower bone mineral density in male teens, according to a new study published in the Endocrine Society’s Journal of Clinical Endocrinology and Metabolism. Endocrine-disrupting chemicals are chemicals or mixtures of chemicals that interfere with the way the body’s hormones work. Per- and...